Proteomic and genetic predictors and risk scores of cardiovascular diseases in persons living with HIV
Authors:
Open Access
- 28 January 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1726272
Abstract
Background: Cardiovascular disease (CVD) prediction models for persons living with HIV (PLWH) depend on traditional CVD risk factors, but these underestimate true risk. We aimed to identify proteins and genetic variants and create proteo-genomic risk scores for CVD in PLWH. Methods: We analyzed genetic and protein data from participants involved in trials for PLWH. We used state-of-the-art statistical methods for data integration, identified correlated signatures, and developed a protein score (PS) and a genetic score (GS) to predict CVD. We conducted functional enrichment analysis to explore biological functions of signatures identified in relation to CVD. Results: A panel of 14 proteins and a set of 15 genetic variants were found to be better at distinguishing between CVD cases and controls than individual proteins or genetic variants. The PS or GS was each independently associated with a higher risk of CVD (OR for PS: 2.36, CI: 1.78–3.19; OR for GS: 4.59, CI: 3.21–6.80). Combining CVD-, HIV-related factors, genetics, and protein scores resulted in the most powerful discrimination with an AUC of 0.86 (CI: 0.82–0.90). Having a PS in the top 25% compared to the bottom 75% resulted in a 3.9 times higher risk of CVD. Having a GS in the top 25% compared to the bottom 75% resulted in a 7.3 times higher risk of CVD. For individuals with both PS and GS in the top 25% compared to others, the risk of CVD was 7.9 times higher. Functional enrichment analysis showed an upregulation of the cytokine tumor necrosis factor (TNF) and strong enrichment for inflammation related pathways such as the pathogen induced cytokine storm. Conclusions: A panel of protein biomarkers, some new (IGFBP7, HGF) and some previously known in PLWH (CLEC6A), could help identify PLWH at higher risk of developing CVD. If confirmed, these scores could be used with CVD and HIV-related factors to identify PLWH at risk for CVD who would benefit from proactive risk reduction strategies.Keywords
Funding Information
- National Institutes of Health
This publication has 41 references indexed in Scilit:
- Assessing Cardiovascular Risk in People Living with HIV: Current Tools and LimitationsCurrent HIV/AIDS Reports, 2021
- Effects of tumour necrosis factor on cardiovascular disease and cancer: A two-sample Mendelian randomization studyEBioMedicine, 2020
- Hepatocyte growth factor is associated with progression of atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA)Atherosclerosis, 2018
- Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart DiseaseJAMA, 2016
- HIV Infection and the Risk of Acute Myocardial InfarctionJAMA Internal Medicine, 2013
- Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersStatistics in Medicine, 2010
- Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyondStatistics in Medicine, 2007
- A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trialThe Lancet, 2006
- Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery diseaseAtherosclerosis, 2006
- THE ROLE OF TNF IN CARDIOVASCULAR DISEASEPharmacological Research, 1999